US EditionPublished • loading... • Updated
Dexcel Pharma USA Acquires US Rights to Zubsolv®
Dexcel Pharma USA acquired U.S. rights to Zubsolv to enhance branded product promotion and maintain access to opioid use disorder therapy, the company said.
- Jan. 7, 2026, Dexcel Pharma USA completed the closing of an Asset Purchase Agreement with Orexo AB to acquire the U.S. rights to Zubsolv and associated commercial infrastructure.
- Dexcel Pharma, the largest private pharmaceutical company in Israel, leverages its R&D and manufacturing facilities to develop quality products and long-term branded product partnerships.
- The company thanked its employees and third-party advisors, including DLA Piper LLP , and Doug Boothe, CEO, said adding Zubsolv will enable Dexcel Pharma USA's strategic U.S. growth.
- The acquisition expands commercial capabilities, and Dexcel Pharma USA said it will work with customers and partners to ensure continued access to Zubsolv for opioid use disorder in the U.S. commercial market.
- The transaction marks a cross-border commercial move by Dexcel Pharma, an Israeli private pharmaceutical group, while the Dexcel Pharma USA press release included a press release multimedia link.
Insights by Ground AI
33 Articles
33 Articles
Buffalo News+32 Reposted by 32 other sources
Dexcel Pharma USA Acquires US Rights to Zubsolv®
Parsippany, N.J., Jan. 7, 2026 /PRNewswire/ -- Dexcel Pharma USA is excited to announce the successful closing of an Asset Purchase Agreement with Orexo AB to acquire the U.S. rights to Zubsolv® (buprenorphine and naloxone) sublingual tablets and the associated…
·Buffalo, United States
Read Full ArticleCoverage Details
Total News Sources33
Leaning Left3Leaning Right0Center13Last UpdatedBias Distribution81% Center
Bias Distribution
- 81% of the sources are Center
81% Center
L 19%
C 81%
Factuality
To view factuality data please Upgrade to Premium
